Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Sales and Divestitures: 2024

  • Stoke Therapeutics' Gains from Sales and Divestitures was N/A to $748,238 in Q4 2024 from the same period last year, while for Dec 2024 it was $748,238, marking a year-over-year change of. This contributed to the annual value of $748,238 for FY2024, which is N/A change from last year.
  • Per Stoke Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $748,238 for Q4 2024.
  • Stoke Therapeutics' 5-year Gains from Sales and Divestitures high stood at $748,238 for Q4 2024, and its period low was $748,238 during Q4 2024.
  • Moreover, its 1-year median value for Gains from Sales and Divestitures was $748,238 (2024), whereas its average is $748,238.